The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 10, 2005
Filed:
Nov. 16, 2000
Cristina Maria Mateo DE Acosta Del Rio, Ciudad Habana, CU;
Lourdes Tatiana Roque Navarro, Ciudad Habana, CU;
Alejo Morales Morales, Ciudad Habana, CU;
Rolando Pérez Rodríguez, Ciudad de la Habana, CU;
Marta Ayala Ávila, Ciudad de la Habana, CU;
Jorge Victor Gavilondo Cowley, Ciudad de la Habana, CU;
Marta Dueñas Porto, Ciudad de la Habana, CU;
Hanssel Bell García, Ciudad de la Habana, CU;
Enrique Rengifo Calzado, Ciudad de la Habana, CU;
Normando Iznaga Escobar, Ciudad de la Habana, CU;
Mayra Ramos Zuzarte, Ciudad de la Habana, CU;
Cristina Maria Mateo de Acosta Del Rio, Ciudad Habana, CU;
Lourdes Tatiana Roque Navarro, Ciudad Habana, CU;
Alejo Morales Morales, Ciudad Habana, CU;
Rolando Pérez Rodríguez, Ciudad de la Habana, CU;
Marta Ayala Ávila, Ciudad de la Habana, CU;
Jorge Victor Gavilondo Cowley, Ciudad de la Habana, CU;
Marta Dueñas Porto, Ciudad de la Habana, CU;
Hanssel Bell García, Ciudad de la Habana, CU;
Enrique Rengifo Calzado, Ciudad de la Habana, CU;
Normando Iznaga Escobar, Ciudad de la Habana, CU;
Mayra Ramos Zuzarte, Ciudad de la Habana, CU;
Centro Inmunologia Molecular, , CU;
Abstract
Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.